These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 29915982)

  • 1. A continuous-time multistate Markov model to describe the occurrence and severity of diarrhea events in metastatic breast cancer patients treated with lumretuzumab in combination with pertuzumab and paclitaxel.
    Xu C; Ravva P; Dang JS; Laurent J; Adessi C; McIntyre C; Meneses-Lorente G; Mercier F
    Cancer Chemother Pharmacol; 2018 Sep; 82(3):395-406. PubMed ID: 29915982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer.
    Schneeweiss A; Park-Simon TW; Albanell J; Lassen U; Cortés J; Dieras V; May M; Schindler C; Marmé F; Cejalvo JM; Martinez-Garcia M; Gonzalez I; Lopez-Martin J; Welt A; Levy C; Joly F; Michielin F; Jacob W; Adessi C; Moisan A; Meneses-Lorente G; Racek T; James I; Ceppi M; Hasmann M; Weisser M; Cervantes A
    Invest New Drugs; 2018 Oct; 36(5):848-859. PubMed ID: 29349598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanistic Investigations of Diarrhea Toxicity Induced by Anti-HER2/3 Combination Therapy.
    Moisan A; Michielin F; Jacob W; Kronenberg S; Wilson S; Avignon B; Gérard R; Benmansour F; McIntyre C; Meneses-Lorente G; Hasmann M; Schneeweiss A; Weisser M; Adessi C
    Mol Cancer Ther; 2018 Jul; 17(7):1464-1474. PubMed ID: 29654069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HALT-D: A Phase II Evaluation of Crofelemer for the Prevention and Prophylaxis of Diarrhea in Patients With Breast Cancer on Pertuzumab-Based Regimens.
    Gao JJ; Tan M; Pohlmann PR; Swain SM
    Clin Breast Cancer; 2017 Feb; 17(1):76-78. PubMed ID: 27692565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer.
    Collins D; Jacob W; Cejalvo JM; Ceppi M; James I; Hasmann M; Crown J; Cervantes A; Weisser M; Bossenmaier B
    PLoS One; 2017; 12(5):e0177331. PubMed ID: 28493933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study.
    van Ramshorst MS; van Werkhoven E; Honkoop AH; Dezentjé VO; Oving IM; Mandjes IA; Kemper I; Smorenburg CH; Stouthard JM; Linn SC; Sonke GS;
    Breast; 2016 Oct; 29():153-9. PubMed ID: 27498129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer.
    Krop IE; Modi S; LoRusso PM; Pegram M; Guardino E; Althaus B; Lu D; Strasak A; Elias A
    Breast Cancer Res; 2016 Mar; 18(1):34. PubMed ID: 26979312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
    Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
    Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pertuzumab for the treatment of human epidermal growth factor receptor type 2-positive metastatic breast cancer.
    Chung C; Lam MS
    Am J Health Syst Pharm; 2013 Sep; 70(18):1579-87. PubMed ID: 23988598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab.
    Swain SM; Schneeweiss A; Gianni L; Gao JJ; Stein A; Waldron-Lynch M; Heeson S; Beattie MS; Yoo B; Cortes J; Baselga J
    Ann Oncol; 2017 Apr; 28(4):761-768. PubMed ID: 28057664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
    Yu AF; Manrique C; Pun S; Liu JE; Mara E; Fleisher M; Patil S; Jones LW; Steingart RM; Hudis CA; Dang CT
    Oncologist; 2016 Apr; 21(4):418-24. PubMed ID: 26984450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer.
    Jhaveri K; Wang R; Teplinsky E; Chandarlapaty S; Solit D; Cadoo K; Speyer J; D'Andrea G; Adams S; Patil S; Haque S; O'Neill T; Friedman K; Esteva FJ; Hudis C; Modi S
    Breast Cancer Res; 2017 Aug; 19(1):89. PubMed ID: 28764748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results.
    Perez EA; López-Vega JM; Petit T; Zamagni C; Easton V; Kamber J; Restuccia E; Andersson M
    Breast Cancer Res; 2016 Dec; 18(1):126. PubMed ID: 27955684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, pharmacokinetics and efficacy findings in an open-label, single-arm study of weekly paclitaxel plus lapatinib as first-line therapy for Japanese women with HER2-positive metastatic breast cancer.
    Inoue K; Kuroi K; Shimizu S; Rai Y; Aogi K; Masuda N; Nakayama T; Iwata H; Nishimura Y; Armour A; Sasaki Y
    Int J Clin Oncol; 2015 Dec; 20(6):1102-9. PubMed ID: 25967286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel.
    Cortés J; Swain SM; Kudaba I; Hauschild M; Patel T; Grincuka E; Masuda N; McNally V; Ross G; Brewster M; Marier JF; Trinh MM; Garg A; Nijem I; Visich J; Lum BL; Baselga J
    Anticancer Drugs; 2013 Nov; 24(10):1084-92. PubMed ID: 23969513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trastuzumab emtansine plus pertuzumab in Japanese patients with HER2-positive metastatic breast cancer: a phase Ib study.
    Noguchi E; Tamura K; Hattori M; Horiguchi J; Sato N; Kanatani K; Matsunaga K; Iwata H; Fujiwara Y
    Breast Cancer; 2019 Jan; 26(1):39-46. PubMed ID: 30039339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accelerating drug development by efficiently using emerging PK/PD data from an adaptable entry-into-human trial: example of lumretuzumab.
    Meneses-Lorente G; McIntyre C; Hsu JC; Thomas M; Jacob W; Adessi C; Weisser M
    Cancer Chemother Pharmacol; 2017 Jun; 79(6):1239-1247. PubMed ID: 28497320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pertuzumab (Perjeta®) approval in HER2-positive metastatic breast cancers].
    Sabatier R; Gonçalves A
    Bull Cancer; 2014; 101(7-8):765-71. PubMed ID: 25091659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pertuzumab-associated diarrhea in HER2/neu-positive breast cancer patients: A comparison of trials to actual practice.
    Yankulina O; Zullo AR; Cabral SE; Huynh JP; Hutchinson JA; Lopresti ML; Fenton MA; Berard-Collins CM
    J Oncol Pharm Pract; 2020 Jun; 26(4):912-917. PubMed ID: 31631811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
    Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
    Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.